Skip to Content
A Research Network of the Division of Cancer Prevention

CCOP - Community Clinical Oncology Program

  1. Home
  2. Contact the Program
  3. For Members

The CCOP Network

The CCOP network has three components, each of which competes for peer-reviewed funding through a Request for Applications.

Three components that comprise the CCOP Network connect under the network banner.

  • Community Clinical Oncology Program (CCOP) site is a single community organization or a consortium of community hospitals and private practices spanning one or several states. These sites enroll patients onto NCI-approved cancer prevention and control clinical trials as well as cancer treatment trials. Each CCOP affiliates with several Research Bases to have access to a choice of studies. CCOPs are required to accrue more than 100 participants per year. In total, the 47 currently funded CCOPs represent 340 hospitals and 2,900 physicians. Twenty-five CCOPs have been continuously funded since 1983.
  • Minority-Based Community Clinical Oncology Program (MB-CCOP) site meets the same requirements as the CCOPs, but must also have a population that is at least 30% minority or underserved. Academic institutions are permitted to be MB-CCOPs. The 16 currently funded MB-CCOPs comprise 55 hospitals and 475 physicians, including 100 minority investigators. Five MB-CCOPs have been continuously funded since 1991.
  • CCOP Research Base (RB-CCOP) is a Cooperative Group or NCI-designated Cancer Center that designs, develops, and conducts cancer prevention and control clinical trials. Cooperative Group CCOP Research Bases also provide cancer treatment clinical trials. Eight Cooperative Groups and four Cancer Centers are currently funded as CCOP Research Bases.

Top

Find a Site in the Network

CCOPs, MB-CCOPs, and RB-CCOPs across the U.S.

Thumbnail of a map of the United States illustrating CCOP sites

View CCOP Network Sites
By Name
By State

Accomplishments (pdf 997kb)

The Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer, with 33% of participants from the CCOPs and MB-CCOPs, demonstrated in 2006 that raloxifene was equivalent to tamoxifen for reducing risk of invasive breast cancer, but with reduced risk of blood clots and uterine cancers. Extended followup, reported in 2010, showed raloxifene was able to reduce risk of noninvasive breast cancer. Raloxifene was approved by FDA in 2007 for reduction of breast cancer risk in postmenopausal women at increased risk.